Absci vs Nabla Bio (2026)
Both design antibodies with generative models and test them in their own laboratories, and they part ways on how far they take a molecule. Absci runs a closed loop it calls Integrated Drug Creation: models design candidates, a synthetic biology engine tests them at a stated billions of cells a week, and the data retrains the models. It has carried an AI designed antibody, ABS-101, into a clinical trial, which puts it ahead of much of the field on stage. Nabla Bio designs antibodies from scratch against the hardest class of target, proteins buried in the cell membrane such as G protein coupled receptors and ion channels, and publishes its results target by target, including the ones it missed. No molecule from its platform has reached a trial yet; its evidence is biochemical and its partnerships, with AstraZeneca, Bristol Myers Squibb and Takeda. Absci is the one to look at when a program wants a generative partner that has already taken a molecule into people. Nabla is the one when the target is a membrane protein where getting any binder at all is the problem.
- A generative platform that has taken an AI designed antibody, ABS-101, into a clinical trial.
- A closed loop that tests designs at a stated billions of cells a week and retrains on the results.
- A public company with a stated six week path from design to a wet laboratory validated candidate.
- De novo antibody design aimed squarely at multipass membrane proteins like GPCRs and ion channels.
- Performance published target by target with denominators, including targets where the model produced nothing.
- Three large pharmaceutical collaborations against the platform, with the results reported zero shot.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Absci and Nabla Bio are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Absci its top capability grade on AI Centrality. Set against Nabla Bio, Absci grades higher on AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Its thinnest published disclosure sits on EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
The AI Health Index awards Nabla Bio its top capability grade on AI Centrality and AI Governance and Bias Disclosure. Set against Absci, Nabla Bio grades higher on Autonomy and Oversight Model, AI Governance and Bias Disclosure and AI Liability and Recourse. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
Questions buyers ask
Should we choose Absci or Nabla Bio?
On the axes where the AI Health Index separates them, Absci grades higher on AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center, and Nabla Bio grades higher on Autonomy and Oversight Model, AI Governance and Bias Disclosure and AI Liability and Recourse. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Absci and Nabla Bio differ most?
The widest separation the AI Health Index records between Absci and Nabla Bio is on AI Governance and Bias Disclosure, where Absci grades C and Nabla Bio grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Absci and Nabla Bio grade the same?
The AI Health Index grades Absci and Nabla Bio the same on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Absci and Nabla Bio not disclosed?
At the last review, at least one of Absci and Nabla Bio published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026, and neither company publishes a price; both earn through partnerships, with Absci also carrying its own clinical program.
Ask both how a partner's target data is kept separate from other programs on the platform, and what either commits to when a designed antibody does not work in the lab.